共查询到20条相似文献,搜索用时 62 毫秒
1.
目的:制备甲磺酸二氢麦角碱缓释片,研究其体外释放特性。方法:以羟丙甲基纤维素(HPMC-K4M)为骨架材料,采用湿法制粒制备甲磺酸二氢麦角碱缓释片。以释放速率、累积释放度为指标,以载药材料(HPMC-K4M)、填充剂(乳糖、磷酸氢钙)和微环境p H调节剂(酒石酸)的用量为因素,采用单因素试验和正交试验对甲磺酸二氢麦角碱缓释片处方进行优化并验证;采用《中国药典》释放度测定方法比较进口和最优处方所制甲磺酸二氢麦角碱缓释片的体外释放特性。结果:最优处方为甲磺酸二氢麦角碱2.5 mg,HPMC-K4M 40 mg,乳糖70 mg,磷酸氢钙80 mg,酒石酸40 mg;所制甲磺酸二氢麦角碱缓释片可体外持续释药12h以上,12 h累积释放度为97.1%,与进口片剂比较累积释放度无明显变化,体外释药行为符合Higuchi方程。结论:成功制得具有缓释作用的甲磺酸二氢麦角碱缓释片。 相似文献
2.
盐酸坦索罗辛缓释片的制备及其体外释药特性研究 总被引:2,自引:1,他引:2
目的:制备盐酸坦索罗辛缓释片,并考察其体外释药特性及机制。方法:以羟丙基甲基纤维素(HPMC)为骨架材料制备坦索罗辛缓释片;以累积释放度为指标,评价多种因素对体外释放速率的影响,并与普通片比较缓释性。结果:HPMC用量及制片压力对释药影响最大,二者最佳值分别为25%、8~11kg时缓释效果最佳,缓释片与普通片0.5h时体外累积释放度分别为10%、50%。结论:所制缓释片缓释效果优于普通片,其释药特性为药物扩散与溶蚀协同作用,释放机制为非Fick扩散。 相似文献
3.
4.
目的 研制盐酸他喷他多12 h缓释片并对其体外释放机制进行初步研究.方法 以HPMC与CMC-Na为混合骨架材料制备缓释片,以单因素试验法对缓释片释放因素进行考察,通过f2相似因子与累积释放度综合评分进行评价,采用正交试验设计筛选最优处方,将自制缓释片与参比制剂的体外释放参数进行比较.结果 最优处方以HPMC K15M和CMC-Na作为混合骨架材料,质量分数各占总质量的40%和12%,乳糖作为致孔剂,质量分数占总质量的12%,微晶纤维素为填充剂,质量分数占总质量的11%.制备的盐酸他喷他多缓释片释放规律符合Ritger-Peppas方程曲线,释药机制为药物扩散和骨架溶蚀协同作用,自制缓释片与参比制剂体外释放行为相似度较高.结论 制得的盐酸他喷他多缓释片有良好的12 h体外释药行为,制备工艺简单、可行,与参比制剂体外释放行为接近,符合缓释制剂要求. 相似文献
5.
目的:制备青藤碱固体脂质纳米粒凝胶骨架缓释片,考察凝胶骨架缓释片处方因素对青藤碱固体脂质纳米粒体外释药行为的影响。方法:采用乳化蒸发-低温固化法制备青藤碱固体脂质纳米粒。以羟丙基纤维素(HPMC)为骨架材料制备青藤碱固体脂质纳米粒凝胶骨架缓释片,单因素考察吸附剂种类、骨架材料比例、PEG种类和骨架材料用量对缓释片体外释药的影响,正交试验进一步优化处方,并对释药模型进行拟合。结果:骨架材料比例和PEG种类是影响青藤碱固体脂质纳米凝胶骨架缓释片体外释药行为的主要影响因素,优化后的处方体外释放行为符合一级释药模型,释药方程为ln(1-Mt/M∞)=-0.187 2 t+0.071 2(r=0.991 1),累积释放度在12 h内可达90.15%。结论:优化后的青藤碱固体脂质纳米粒凝胶骨架缓释片制备工艺简单,重复性良好,在12 h内具有良好的体外缓释特征。 相似文献
6.
7.
目的:优化去甲斑蝥素缓释片制备处方及考察其释药特性。方法:以羟丙基甲基纤维素(HPMC)为骨架材料制备去甲斑蝥素亲水凝胶缓释骨架片;以HPMC用量(A)、乳糖用量(B)、乙醇浓度(C)、乙醇用量(D)为因素,以体外释放度综合评分值为指标筛选缓释片的最佳处方并考察其累积释药率。结果:缓释片的最佳处方为A12g、B1.5g、C90%、D10mL;所制缓释片2、6、12h的累积释药率分别为(30.63±1.03)%、(51.70±1.51)%、(89.25±1.04)%,药物释放机制为扩散和骨架溶蚀的协同作用。结论:优化处方制备的去甲斑蝥素缓释片可以达到预期缓释效果。 相似文献
8.
9.
10.
目的:制备氢溴酸右美沙芬缓释片,进行体外释放度研究.方法:采用亲水性高分子材料HPMC为凝胶骨架,制备氢溴酸右美沙芬缓释片,并制订体外释放度检测方法.结果:所制备的缓释片12h内呈现良好的缓释特性,符合Higuchi方程.结论:所制的缓释片体外释药缓慢、平稳,符合设计要求. 相似文献
11.
12.
13.
The prevention of histamine-induced gastric and duodenal ulceration in the guinea-pig has been examined using a series of undegraded and degraded carrageenans. Undegraded carrageenans were active at lower doses than degraded carrageenans. The high viscosity of the undegraded carrageenans in solution prevented their use in larger doses. Degradation of carrageenan without serious loss of sulphate, gives a product which allows the dose to be increased to an extent that its effect more than offsets the slight loss in activity caused by the degradation. No single feature of carrageenan structure can be related to anti-ulcer activity although degradation, and hence reduction of molecular size, generally reduces activity. Sulphate contents over 30% have little apparent effect on activity; κ-carrageenans were not consistently different in anti-ulcer activity from Λ-carrageenans. This contrasts with the antipeptic activity of carrageenans where κ-carrageenans are less active than their Λ-counter-parts. As with antipeptic activity, the degree of anti-ulcer activity is probably determined by a combination of structural features which includes molecular size and polyanionic properties. 相似文献
14.
15.
Larks and owls and health, wealth, and wisdom 总被引:1,自引:0,他引:1
16.
17.
《Journal of addictive diseases》2013,32(3):73-87
Depression and anxiety frequently coexist in patients with substance use disorders. This clinically-oriented article examiens the relationship between these conditions and emphasizes data showing that substances of abuse can cause signs and symptoms of both depression and anxiety. These substance-related syndromes appear to have a different course and prognosis than uncomplicated, independent anxiety and major depressive disorders, and clinicians should consider the role of alcohol and other drugs in all patients presenting with these complaints. The authors will also outline an approach for diagnosing and managing patients with the combination of a substance use and depressive or anxiety disorder. 相似文献
18.
19.
20.
Z J Witczak 《IDrugs : the investigational drugs journal》1998,1(1):30-31
The American Chemical Society Symposium "Glucosidase and fucosidase inhibitors" took place on 1 April 1998 and was organized by Professors Zbigniew J Witczak (UConn, School of Pharmacy, CT, USA), Kuniaki Tatsuta (Waseda University, Tokyo, Japan) and Waldemar Priebe, MD (Anderson Cancer Center, University of Texas, USA). Professor Witczak provided introductory remarks including the status of existing glucosidase inhibitors, and chaired the morning session, which consisted of six lectures. The symposium was well received, and was particularly attractive for those interested in networking, as attendance was about sixty. In addition, some participants and attendees presented posters on the subject during the regular poster session organized by the Division of Carbohydrate Chemistry. 相似文献